Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant imatinib after surgery for intermediate- or high-risk gastrointestinal stromal tumor
ChiCTR-TNC-09000582Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Recurrence-free survival. Started Jan 2004; status: completed.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ChiCTR-TNC-09000582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-09000582.